Figure 2.

Changes in ALC, ANC, and platelet count after initiation of treatment with baricitinib+remdesivir vs. placebo+remdesivir in hospitalized patients with COVID-19.

Panel A shows distributions of ALC, ANC, and platelet count at baseline (yellow) and at day 5 (blue) by risk quartile and treatment group. Panel B shows the distributions of ratio change in hematologic parameters from baseline to day 5 in the high-risk quartile and in the overall study population by treatment group. The center of the ratio change distribution is quantified by the geometric mean of the ratio change with the 95% CI. P values are from t tests on the log-transformed ratio changes. ALC = absolute lymphocyte count; ANC = absolute neutrophil count.